AI protein design market seen hitting $5.68 billion by 2030

The artificial intelligence protein design market is forecast to grow from $2.13 billion in 2026 to $5.68 billion by 2030, driven by drug discovery, biologics and precision medicine demand. North America leads now, while Asia-Pacific is expected to grow fastest.

Why it matters: - AI protein design is moving from a research tool into a core part of drug discovery and protein engineering. - The market’s projected growth signals rising demand for faster development of biologics, enzymes and custom therapeutics. - The expected expansion also points to broader adoption of AI across life sciences, cloud computing and advanced modeling.

What happened: - The Business Research Company projected the AI protein design market will rise from $2.13 billion in 2026 to $5.68 billion by 2030. - The forecast implies a 27.7% compound annual growth rate through 2030. - The company said the market was valued at $1.67 billion in 2025 and is expected to reach $2.13 billion in 2026. - The report was released July 15, 2026. - A free sample of the report is available. - The full report is also available online.

The details: - AI protein design uses machine learning and computational models to predict, generate and optimize protein structures for specific functions. - The approach analyzes biological datasets to identify patterns in amino acid sequences and protein folding behavior. - The technology supports the creation of novel proteins that may not occur naturally. - The report links market growth to advances in computational biology and bioinformatics. - Other growth drivers include expanding genomic and proteomic data, wider use of structural biology techniques such as x-ray crystallography, higher pharmaceutical R&D spending and more academic research on protein folding and molecular biology. - Looking ahead, the report points to more use of AI-powered drug discovery platforms, cloud computing in life sciences, precision medicine, synthetic biology, engineered proteins and quantum computing for protein modeling. - The report highlights de novo protein structure prediction, machine learning-enabled enzyme engineering, cloud-based protein simulations, generative AI for therapeutic proteins and antibodies, and high-throughput virtual screening as key trends. - The report says biologics are a major driver because AI can speed design and refinement while improving therapeutic effectiveness, stability and specificity. - The World Health Organization reported in February 2025 that 81 biologic therapies were included in the 2023 WHO Essential Medicines List, representing more than 15% of all listed medicines. - Personalized and precision medicine is also boosting demand for protein design tools that can support customized therapies. - North America was the largest AI protein design market in 2025. - Asia-Pacific is expected to grow fastest during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast suggests AI protein design is becoming commercially relevant as biopharma looks for faster and more targeted ways to develop treatments. - The emphasis on biologics and precision medicine shows the market is being pulled by clinical demand, not just technical innovation. - The mention of quantum computing signals that the sector is still early, with room for new computing methods to change protein modeling.

What’s next: - The market’s next phase will likely center on better protein prediction tools, broader cloud-based workflows and more automated therapeutic design. - Regional growth may shift toward Asia-Pacific as biotech investment and AI adoption accelerate. - The Business Research Company said the 2026 edition of its reports adds market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards and hotspot graphics.

The bottom line: - AI protein design is emerging as a fast-growing market with direct applications in drug discovery, biologics and precision medicine, and the growth outlook through 2030 is strong.